Por favor, use este identificador para citar o enlazar este ítem: 10.14670/HH-11-643

Título: Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors
Fecha de publicación: 2015
Editorial: F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
Cita bibliográfica: Histology and histopathology, Vol. 30, nº10, (2015)
ISSN: 1699-5848
0213-3911
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
Palabras clave: Isocitrate dehydrogenase 1/2 (IDH1/IDH2)
Mutations
Methylation
Metabolism
Tumorigenesis
Resumen: In recent years, frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations were found in a variety of tumors, which specifically alter arginine residues of catalytic active site in IDH1/IDH2 and confer new enzymatic function of directly catalyzing alpha-ketoglutarate (α-KG) to R-2-hydroxyglutarate (2- HG). 2-HG could competitively inhibit α-KG–dependent enzymes and might therefore contribute to tumorigenesis. In addition, mutation status of IDH1/IDH2 is closely related to the progress and prognosis of certain tumors. Thus IDH1/IDH2 is considered to be a promising biomarker for early diagnosis and prognosis and targeted therapy. In this study, the current research on IDH1/IDH2 mutation, especially the mechanisms and clinical characteristics related to tumor, are reviewed.
Autor/es principal/es: Liu, Xiang
Ling, Zhi-Qiang
URI: http://hdl.handle.net/10201/100050
DOI: 10.14670/HH-11-643
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 6
Derechos: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 International
Aparece en las colecciones:Vol.30,nº10 (2015)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Liu-30-1155-1160-2015.pdf572,01 kBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons